Grant · National Institutes of Health
Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Require
- Type
- Grant
- Organisation
- National Institutes of Health
- Deadline
- 19 November 2026
- Posted
- 22 November 2024
About this listing
Funding opportunity PAR-25-226 from National Institutes of Health.
Last checked 2 October 2026. Found via Grants.gov: federal research funding. The official page opens for members.